LSB logo

LSB LakeShore Biopharma Co., Ltd

NASDAQ Capital Market · Biotechnology · Healthcare

$0.63
+0.00 (+0.00%)

LakeShore Biopharma Co., Ltd is a biopharmaceutical firm focused on the discovery, advancement, manufacturing, and marketing of vaccines and therapeutic biologics. Its primary targets are infectious diseases and various forms of cancer. At the core of its innovation is a proprietary PIKA immunomodulating technology platform, which underpins its product pipeline, featuring a PIKA rabies vaccine, a …

Market Cap: $25.84Mwww.ysbiopharm.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

125
125
Aug 16Aug 16

Quote

Day Range
$0.63 – $0.79
52-Week Range
$0.57 – $8.60
Volume
$658.3K
Market Cap
$25.84M
50-Day Avg
$0.87
200-Day Avg
$1.69
Prev Close
$0.63
Open
$0.79

Valuation & Ratios

P/E Ratio
-18.91
EPS
$-0.94
P/B Ratio
3.80
P/S Ratio
3.09
Debt/Equity
0.83
Current Ratio
1.02
Dividend Yield
+0.0%
Gross Margin
+82.5%

Returns & Efficiency

Return on Equity
-20.0%
Return on Assets
-7.3%
FCF Yield
-7.3%
EV/EBITDA
-47.12

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$614.96M$-99.98M$-0.94
2024$573.42M$-433.46M$-4.05
2023$687.20M$-145.48M$-1.88
2022$502.95M$-236.67M$-0.02
2021$257.02M$-191.83M$-6.67

Social Signal Score

75
5d
76
1 mentions
30d
75
1 mentions
60d
75
1 mentions
90d
75
1 mentions
news: 1

Earnings

0of 4 quarters beat consensus

Typical surprise -100.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Apr 18$-1.20 vs $-0.60miss
  • Mon, Jan 27$-1.60 vs $-0.80miss
  • Tue, Sep 24$-1.34 vs $-0.58miss
  • Fri, Apr 19$-0.12 vs $-0.09miss

Estimates and results for LSB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by LSB officers and directors.

No open-market trades in the recent filings. All 8 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.

8 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

LSBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsseekingalpha.com·5h ago·Positive

    LSB Industries: Why Cost Advantage Makes It A Buy LSB Industries is rated Buy with a $13.50 target, leveraging a structural U.S. natural gas cost advantage over European peers. Operational efficiency gains, particularly at the El Dorado plant, and a flexible product mix support margin expansion and resilience against agricultural price swings. The carbon capture project is expected to generate $25–30 million in annual cash flow by 2027, with regulatory and execution risks to monitor.

    View source ↗